Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrZZ2dKSzVyPUCuNFI5ODZizszN M{jHR3NCVkeHUh?=
KS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEO4N|Uh|ryP M2DXenNCVkeHUh?=
TE-11 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEe4NlIh|ryP MonQV2FPT0WU
EW-1 NHf1TVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrLOVlMUUN3ME2wMlA5PTh3IN88US=> NIXmOVJUSU6JRWK=
HMV-II M1jLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK5SJlKSzVyPUCuNFg5PDZizszN NY\6foxwW0GQR1XS
COLO-205 M{n4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUC0OVQh|ryP M3zt[HNCVkeHUh?=
ES1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMUC2PVYh|ryP NEfRZ5NUSU6JRWK=
GDM-1 NHjudnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUO2O|Ih|ryP MoS5V2FPT0WU
ML-2 NWn2VoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnhTWM2OD1yLkG1PFk3KM7:TR?= NUK1[ldiW0GQR1XS
Saos-2 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLSTWM2OD1yLkG2OVI3KM7:TR?= MYfTRW5ITVJ?
NCI-H1355 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELJ[G5KSzVyPUCuNVgyOzVizszN NXjrRnVlW0GQR1XS
G-401 M4j1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\1[pNKSzVyPUCuNVgzOyEQvF2= MWrTRW5ITVJ?
EW-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vISWlEPTB;MD6xPFc4PyEQvF2= M3v4TXNCVkeHUh?=
EW-7 M3zyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMUi4PFEh|ryP MVLTRW5ITVJ?
NCI-H727 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HFdWlEPTB;MD6xPVc6PCEQvF2= NVLsPXJmW0GQR1XS
LCLC-97TM1 NF7MbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJV2pKSzVyPUCuNlA6PTVizszN NYPGcGFmW0GQR1XS
NCI-H650 M37uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7vV4tSUUN3ME2wMlIyOzh2IN88US=> MULTRW5ITVJ?
NCI-H2122 NV3pd2tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqwV5dLUUN3ME2wMlI{Ojl7IN88US=> M37URXNCVkeHUh?=
SK-N-DZ NXThVW57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMkO2PVgh|ryP NHjOWHJUSU6JRWK=
HT-29 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7OZmNKSzVyPUCuNlQzPDhizszN NXLlcYdRW0GQR1XS
LB771-HNC M1LQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13CcWlEPTB;MD6yOVkyPSEQvF2= NGTVVZJUSU6JRWK=
HT-144 NFHuSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nMbGlEPTB;MD6yOlE6OSEQvF2= MXPTRW5ITVJ?
LAN-6 NGfpSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7CZ2xKSzVyPUCuNlY{PDhizszN M3HsWHNCVkeHUh?=
EW-18 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzmeIpHUUN3ME2wMlI4ODBzIN88US=> MVHTRW5ITVJ?
LS-1034 NV3p[2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD1yLkK3NVMzKM7:TR?= NH;VNoxUSU6JRWK=
EW-11 NYHOSGJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zW2lEPTB;MD6yPFQ{OiEQvF2= NEf0fZNUSU6JRWK=
SNU-C1 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTWTJNKSzVyPUCuNlk{OTNizszN MUPTRW5ITVJ?
RS4-11 NY\FbZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1TWM2OD1yLkOzO|U5KM7:TR?= M2LhcXNCVkeHUh?=
ES4 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwNEGwN|gh|ryP M3n0dHNCVkeHUh?=
COLO-320-HSR NHTrc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqOWlEPTB;MD60NVM3QCEQvF2= MkSzV2FPT0WU
NB10 NUDRWXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNEW0N|ch|ryP NV3XSZZOW0GQR1XS
BFTC-905 NXvBXZF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD1yLkS2O|U5KM7:TR?= MYnTRW5ITVJ?
A375 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i4eWlEPTB;MD60O|YyPyEQvF2= NV;aNYtIW0GQR1XS
SJRH30 M1f6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNUC4NlIh|ryP M1zrTnNCVkeHUh?=
NOS-1 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLoNo9KSzVyPUCuOVIzPjdizszN MXjTRW5ITVJ?
SIG-M5 NV70cFhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfCTWM2OD1yLkWzOVU4KM7:TR?= MmfXV2FPT0WU
DOK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNUW2JO69VQ>? M{KwcHNCVkeHUh?=
NB69 NH\seo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmTWM2OD1yLkW4NlU4KM7:TR?= NYTZe|F1W0GQR1XS
SK-NEP-1 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL5TWM2OD1yLk[wNlM3KM7:TR?= MkKyV2FPT0WU
SK-MM-2 M2CwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNkW0PVEh|ryP M{nTdHNCVkeHUh?=
NCI-H358 M4DHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD1yLk[3NFgzKM7:TR?= M{PFb3NCVkeHUh?=
RH-1 NF7MZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPMTWM2OD1yLke0PFU6KM7:TR?= NXTuO|M4W0GQR1XS
NH-12 M2flV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xm[2lEPTB;MD63OlA1PiEQvF2= M1W5XHNCVkeHUh?=
TE-12 NIjYZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3cGlEPTB;MD63OlQ5PiEQvF2= MYLTRW5ITVJ?
COLO-668 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTEOnNKSzVyPUCuPFQ3PjZizszN MX3TRW5ITVJ?
PANC-08-13 NGraZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH6TWM2OD1yLki2N|c4KM7:TR?= NYrNOoZYW0GQR1XS
HCC2998 NEm0RoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzW[5dKSzVyPUCuPFgzPjNizszN Mo[0V2FPT0WU
ABC-1 NGruO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUCzOVIh|ryP NXGzfGlqW0GQR1XS
ES6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwOUGwOlYh|ryP M1\YPHNCVkeHUh?=
SNU-387 M3X4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\UeZFKSzVyPUCuPVk{QTNizszN M3HmZnNCVkeHUh?=
CMK MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\kV5RKSzVyPUCuPVk6OjlizszN MUPTRW5ITVJ?
SJSA-1 M2PpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TzTGlEPTB;MT6wN|Y2OyEQvF2= NUjqNVY{W0GQR1XS
SIMA MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnlTWM2OD1zLkC2PFI2KM7:TR?= NFToTFFUSU6JRWK=
ES3 M{jad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwMUKyPVch|ryP MVfTRW5ITVJ?
IGROV-1 M2ryXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C3S2lEPTB;MT6xOVQ1PCEQvF2= M4Ttd3NCVkeHUh?=
MEL-JUSO NFvUe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTMTWM2OD1zLkG1O|U6KM7:TR?= NIm5ZXJUSU6JRWK=
T84 NVjWeJd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwMkC5NVQh|ryP M{DXO3NCVkeHUh?=
CAL-85-1 NEf3e|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LpfWlEPTB;MT6yN|E{QCEQvF2= NWG3Z2NRW0GQR1XS
RD NGrJfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr3bFA2UUN3ME2xMlI3PDV3IN88US=> MkToV2FPT0WU
TE-8 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwM{G0OlIh|ryP NXnJTlhqW0GQR1XS
L-363 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwM{SyNFgh|ryP MYDTRW5ITVJ?
EKVX MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXsNYxKUUN3ME2xMlM1PTZ6IN88US=> M4PRW3NCVkeHUh?=
SK-MEL-3 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mzfGlEPTB;MT60PFU2PiEQvF2= NXTaSnNmW0GQR1XS
TGBC24TKB Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwNUCxPVMh|ryP MnmxV2FPT0WU
NCI-H1770 NXjCVYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzETWM2OD1zLkWxNVE{KM7:TR?= MYTTRW5ITVJ?
HuH-7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXnbJhTUUN3ME2xMlYxODl6IN88US=> NV;ycWNCW0GQR1XS
HL-60 NF;vb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D2fGlEPTB;MT62OlkzQCEQvF2= MlnhV2FPT0WU
TE-1 M2r3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nWUmlEPTB;MT63NFk1PSEQvF2= MmrmV2FPT0WU
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP5TWM2OD1zLkezPFg4KM7:TR?= MnXnV2FPT0WU
LB647-SCLC M3;4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwN{[1PFMh|ryP MVTTRW5ITVJ?
NCI-H2171 NHTSO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwN{e3NVYh|ryP MYjTRW5ITVJ?
SK-PN-DW Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjWTWM2OD1zLkmxNlk5KM7:TR?= NH76TopUSU6JRWK=
MC-IXC NUe0Spc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfUdXQ3UUN3ME2xMlk5QThizszN MVTTRW5ITVJ?
LS-513 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\UTWM2OD1{LkC1N|A2KM7:TR?= Ml70V2FPT0WU
EW-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwMEm4OFQh|ryP M1y1[3NCVkeHUh?=
OPM-2 NGX5S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm0TVlKSzVyPUKuNVAzKM7:TR?= NYr5dGhWW0GQR1XS
LP-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3VVHVyUUN3ME2yMlI2QDB5IN88US=> MmHRV2FPT0WU
LU-134-A M2jCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHrTWM2OD1{LkK3O{DPxE1? NIToWVZUSU6JRWK=
CP66-MEL NXzESWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTKTWM2OD1{LkK5NFE1KM7:TR?= M4ruTXNCVkeHUh?=
HCC1143 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fVVGlEPTB;Mj60OVM3QCEQvF2= NI\TeXBUSU6JRWK=
LOXIMVI MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHhTWM2OD1{Lk[wNlEh|ryP M1P1ZnNCVkeHUh?=
TE-10 M3PNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe0VVhiUUN3ME2yMlcxQDN6IN88US=> MnnZV2FPT0WU
NCI-H1882 NELzU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjCTWM2OD1{Lke1NlI4KM7:TR?= NWnyfGZ{W0GQR1XS
CHP-126 NF7FNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu5TWM2OD1{Lke2N|E4KM7:TR?= NGCxfXRUSU6JRWK=
NCI-H1623 M2jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;5W3dKSzVyPUKuPVIxOjRizszN MXrTRW5ITVJ?
GB-1 NYXHV|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwOUO0NFQh|ryP M{HjbXNCVkeHUh?=
RCC10RGB M{DTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TTWmlEPTB;Mj65OVI5OSEQvF2= NYXifJFGW0GQR1XS
NCI-H2141 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwOU[4PVYh|ryP M{D2dHNCVkeHUh?=
GI-ME-N Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTqcnhtUUN3ME2zMlAxPTZ3IN88US=> NWH0c25mW0GQR1XS
NCI-H526 NFq0XINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TxcWlEPTB;Mz6wOFA5PSEQvF2= NGjiVWFUSU6JRWK=
NCI-H747 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfaO2VnUUN3ME2zMlA1QTl{IN88US=> NUnVTmNFW0GQR1XS
SNU-423 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LzfmlEPTB;Mz6yNFMyOyEQvF2= MX7TRW5ITVJ?
A427 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\3XlZKSzVyPUOuNlU3QTlizszN MnLrV2FPT0WU
CAL-12T NYDaZlI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYSGlEPTB;Mz60NFcyOyEQvF2= Ml3QV2FPT0WU
LU-99A MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Pc|ZrUUN3ME2zMlQ4OTB3IN88US=> NIrCTVBUSU6JRWK=
MS-1 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwNUO0Nlkh|ryP Moj0V2FPT0WU
SK-LU-1 NIP6VWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmxTWM2OD1|Lke2Nlk2KM7:TR?= MVrTRW5ITVJ?
SW837 M1nhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor0TWM2OD1|Lke2N|M{KM7:TR?= MYTTRW5ITVJ?
ES8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2S4hKSzVyPUOuPFM5PzdizszN MW\TRW5ITVJ?
MZ2-MEL NHPQbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwOUKwPFYh|ryP MWDTRW5ITVJ?
TGW M2rmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrWeo96UUN3ME20MlAyOzFzIN88US=> NWnqOVlRW0GQR1XS
GP5d NX7XWpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD12LkC1N|YzKM7:TR?= NUP1[pRrW0GQR1XS
BB49-HNC NFP4eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwMUWyNVMh|ryP NG\OOm1USU6JRWK=
NB13 NX7uU|ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\zTFBKSzVyPUSuNlY5QDdizszN MmXxV2FPT0WU
NTERA-S-cl-D1 NEmxZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRwMki2NVUh|ryP MlLLV2FPT0WU
NCI-H1648 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknwTWM2OD12LkK5PFE6KM7:TR?= M3ixRnNCVkeHUh?=
LCLC-103H NEHMU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETUOGxKSzVyPUSuN|IyQTVizszN NEfVV2hUSU6JRWK=
LS-411N MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXXdGdpUUN3ME20MlQ1QDh3IN88US=> MVHTRW5ITVJ?
NCI-H1092 NV7zTG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH2TWM2OD12LkS1Olg4KM7:TR?= NFv2T2FUSU6JRWK=
PANC-10-05 NUjpb45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXjTGx3UUN3ME20MlY6QDRizszN MnTaV2FPT0WU
DK-MG NELrclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHETWM2OD12LkiwPVM{KM7:TR?= MVHTRW5ITVJ?
OVCAR-5 NHTrbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnWdplKSzVyPUSuPFEzOjZizszN MojJV2FPT0WU
CAL-39 M2rPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftdWlEPTB;ND64O|Y4KM7:TR?= NIDyZlRUSU6JRWK=
TE-441-T NH3PeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCxTWM2OD12LkmwOVM4KM7:TR?= M{DjXHNCVkeHUh?=
MOLT-16 NYrTc3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwOUWyOVMh|ryP M1LTW3NCVkeHUh?=
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GR5pKSzVyPUWuNVQ2OTdizszN MmT4V2FPT0WU
CAPAN-1 NEfIZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjrcG4xUUN3ME21MlI2PzB5IN88US=> M2TjWnNCVkeHUh?=
PSN1 NFLYfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwMkeyN|Uh|ryP MXzTRW5ITVJ?
NCI-H292 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVwM{CwOFQh|ryP MXTTRW5ITVJ?
CPC-N MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrzS49rUUN3ME21MlM6PDF7IN88US=> NYfSbIZrW0GQR1XS
DoTc2-4510 M1zrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe2bWo6UUN3ME21MlQ2OzdzIN88US=> Mm\EV2FPT0WU
LB1047-RCC M3HTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X5U2lEPTB;NT61OVk{OyEQvF2= NH3s[Y9USU6JRWK=
MHH-ES-1 M2LSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTVwNUm5NFch|ryP NH7BU2pUSU6JRWK=
NMC-G1 NUnLc2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjFbGFKSzVyPUWuO|AzOjdizszN MYPTRW5ITVJ?
SW1710 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHaTWM2OD13Lke0O|UyKM7:TR?= NY\4eFN1W0GQR1XS
YAPC NUPzXIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3n[ZMxUUN3ME21Mlc3OjBzIN88US=> NIjldXhUSU6JRWK=
22RV1 NEXtVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK2TWM2OD13LkiwNFE6KM7:TR?= MkDlV2FPT0WU
COLO-679 NIrKTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjkfXZFUUN3ME21Mlg5QTR6IN88US=> NEn5SmNUSU6JRWK=
TCCSUP MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULsRVBmUUN3ME21Mlk{OjV7IN88US=> NV3lSYRkW0GQR1XS
C2BBe1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTVwOUO5O{DPxE1? NIe3eGRUSU6JRWK=
TE-15 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rEZmlEPTB;Nj6wOlYxPSEQvF2= MnHJV2FPT0WU
SCLC-21H NUDEVYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZwMUC4OFMh|ryP NWC1NpVFW0GQR1XS
EoL-1-cell MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3KTWM2OD14LkG2OVY{KM7:TR?= Mn\lV2FPT0WU
NKM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nmTmlEPTB;Nj6xOlcyKM7:TR?= M2Hw[HNCVkeHUh?=
NCI-H1304 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3eGlEPTB;Nj6yO|QzQCEQvF2= NXv1So1bW0GQR1XS
NB6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7reo0xUUN3ME22MlI6PjJ{IN88US=> MVjTRW5ITVJ?
NALM-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvTTWM2OD14LkOzNlMh|ryP NFj5OI1USU6JRWK=
NCI-H522 M4jFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6ZWlEPTB;Nj6zN|MxPiEQvF2= NEXDUI1USU6JRWK=
MV-4-11 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jqUWlEPTB;Nj6zO|A4QSEQvF2= NYnsfXdjW0GQR1XS
LB2241-RCC M4LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPrfYVMUUN3ME22MlM5PjZ5IN88US=> M1zSV3NCVkeHUh?=
NCI-H1417 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG4OZIxUUN3ME22MlQxQDR5IN88US=> MkP4V2FPT0WU
HT-1197 NGqx[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZwNUexNlIh|ryP MUTTRW5ITVJ?
P30-OHK NHTkWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3SZpFYUUN3ME22MlYzPzdizszN M1y5bHNCVkeHUh?=
ALL-PO NInQPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHicoZKSzVyPU[uO|E6OTZizszN NHewe5dUSU6JRWK=
OVCAR-4 M4fMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[yUnpXUUN3ME22Mlc2PDB3IN88US=> MUjTRW5ITVJ?
HCC2157 M{DFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7C[HdkUUN3ME22Mlc4PDd3IN88US=> M2LYPXNCVkeHUh?=
NCI-H838 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\WWpc5UUN3ME22Mlk3PDlizszN MkPBV2FPT0WU
NCI-H1299 M1;zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHzSnF4UUN3ME22Mlk4ODlizszN MmrJV2FPT0WU
SW954 NHX0PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnTV|VKSzVyPUeuNlAxPjhizszN M2TKOXNCVkeHUh?=
NCI-H441 NXTtOVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTJeW5kUUN3ME23MlM1ODZ3IN88US=> MYXTRW5ITVJ?
SK-MEL-2 NH;SXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT3VIRKSzVyPUeuOFg{PzNizszN Mn;TV2FPT0WU
KARPAS-45 M1rvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTdwNkW5Nlkh|ryP MWDTRW5ITVJ?
CAL-54 NWnaPXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPCbYhUUUN3ME23MlgzQTd5IN88US=> MkTMV2FPT0WU
KYSE-180 M17sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT5TWM2OD15Lki4PVQyKM7:TR?= NH;ocWdUSU6JRWK=
NCI-H187 NYTkTmdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuXnhKSzVyPUeuPVU6PDdizszN M2fmXXNCVkeHUh?=
RT-112 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLncnc4UUN3ME24MlA6Pjd5IN88US=> M3LUVXNCVkeHUh?=
NCI-H1437 NEDxUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPpTWM2OD16LkC5O|k2KM7:TR?= M2LyO3NCVkeHUh?=
SNU-449 NEjDepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvkRmdKSzVyPUiuNlgzPzJizszN M1nNSHNCVkeHUh?=
HCC1187 M3nOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLyTmZjUUN3ME24MlI6OzlzIN88US=> M{PvZ3NCVkeHUh?=
NCI-H2030 M3fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjrcnVKSzVyPUiuN|c4OTRizszN MlfpV2FPT0WU
HuO-3N1 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfPc3V5UUN3ME24MlM4QDR2IN88US=> NHq4cGJUSU6JRWK=
COLO-792 NXXj[Yh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRThwNEG1Nlch|ryP NWXDdpBOW0GQR1XS
MIA-PaCa-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGwOohKSzVyPUiuPFU2ODhizszN Mo\jV2FPT0WU
SK-N-FI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T2OGlEPTB;OT6wOFI2KM7:TR?= NF;pbWxUSU6JRWK=
MMAC-SF NYjncWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5NmJMUUN3ME25MlA6PzVzIN88US=> NX3yU3AxW0GQR1XS
NCI-H28 NWmxW5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPwS|B6UUN3ME25MlExPDZ7IN88US=> NYi0[ZJVW0GQR1XS
ETK-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmraTWM2OD17LkK5PVc1KM7:TR?= NGn0RnRUSU6JRWK=
NCI-H1993 M3:weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD17LkS0NlYyKM7:TR?= NV61VZNtW0GQR1XS
no-11 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW3TGZKSzVyPUmuOFcyOiEQvF2= NUCzeoNVW0GQR1XS
ChaGo-K-1 M3znW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TVcmlEPTB;OT61NVU5OyEQvF2= MUjTRW5ITVJ?
NCCIT NFPPeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlwNUOxOlkh|ryP M2\tfXNCVkeHUh?=
SAS NHe4cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXGc29KSzVyPUGwMlI1QCEQvF2= M2fNcXNCVkeHUh?=
A673 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTGTWM2OD1zMD6zO|A1KM7:TR?= NUHtNnJnW0GQR1XS
NCI-H1522 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDqTWM2OD1zMD6zO|A4KM7:TR?= MYnTRW5ITVJ?
NCI-H810 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOyd4FpUUN3ME2xNE4{QTB5IN88US=> MV7TRW5ITVJ?
IST-MES1 NVfnVHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTSTG55UUN3ME2xNE41PTZ2IN88US=> NYjZenRJW0GQR1XS
GR-ST M4LVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED1WGdKSzVyPUGwMlUxOjRizszN MUTTRW5ITVJ?
SUP-T1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPDTWM2OD1zMD63N|E4KM7:TR?= NHuwb2hUSU6JRWK=
NB5 NI\jfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyxTWM2OD1zMD65NFIzKM7:TR?= NHS3eXVUSU6JRWK=
MZ1-PC NEjDV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ITWM2OD1zMD65OVcyKM7:TR?= NWHiPVJ2W0GQR1XS
SK-CO-1 NW\vbYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLkm5N|Eh|ryP M3q3O3NCVkeHUh?=
Capan-2 NVTTUlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTCfYpJUUN3ME2xNU4{OTl6IN88US=> NEn6RW5USU6JRWK=
697 NVPWOlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojjTWM2OD1zMT62O|U4KM7:TR?= NWnv[|h1W0GQR1XS
REH NFjUNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXNTWM2OD1zMT63OFUyKM7:TR?= M2PLVXNCVkeHUh?=
GI-1 M{[3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfJTWM2OD1zMT64OlE2KM7:TR?= MlPEV2FPT0WU
BB65-RCC NGHablRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXOSFFKSzVyPUGyMlA6OTZizszN MoLUV2FPT0WU
NCI-H1651 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULre3FGUUN3ME2xNk4zPDd6IN88US=> MXXTRW5ITVJ?
NCI-H1618 M1;K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfkTHZEUUN3ME2xNk4{QTd4IN88US=> NFvmVJBUSU6JRWK=
NCI-H2081 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\WXGlEPTB;MUKuOlE1OSEQvF2= MkPDV2FPT0WU
GCIY M4T1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD1zMj63NlE{KM7:TR?= MmXhV2FPT0WU
NY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHrNIlQUUN3ME2xN{4xPjR|IN88US=> MXvTRW5ITVJ?
PANC-03-27 NGrBUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfMclBlUUN3ME2xN{4xQDB5IN88US=> NF;JPGZUSU6JRWK=
BHY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MeWlEPTB;MUOuNlEzOSEQvF2= MYrTRW5ITVJ?
SK-OV-3 NVPhT3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fmdWlEPTB;MUOuN|c3OyEQvF2= MYPTRW5ITVJ?
5637 M{DDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\yd3lKSzVyPUGzMlc4PTlizszN NH;MUoJUSU6JRWK=
LC-1F MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF2LkCzOVYh|ryP M3PK[HNCVkeHUh?=
SNB75 M4PFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WxU2lEPTB;MUSuNFM5OyEQvF2= M4fle3NCVkeHUh?=
CHP-212 M4PGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PBZWlEPTB;MUSuNFQ3PCEQvF2= Mk\IV2FPT0WU
HT-1376 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\MUWlEPTB;MUSuNVEzPiEQvF2= NHrLVFBUSU6JRWK=
MONO-MAC-6 M1vLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF2LkG1NFIh|ryP MnjhV2FPT0WU
CA46 NUTReFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\1PYJKSzVyPUG0MlE5OjdizszN MVzTRW5ITVJ?
SCC-15 NW\CWXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H0RWlEPTB;MUSuOVU5OyEQvF2= NEjrOZhUSU6JRWK=
ATN-1 NVe1[25ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF2Lk[2Nlch|ryP NH\TeI9USU6JRWK=
NCI-H2405 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxOHhVUUN3ME2xOE45OTV5IN88US=> M1HIWnNCVkeHUh?=
NCI-H716 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\pOFN[UUN3ME2xOE45PDl|IN88US=> M4f1cXNCVkeHUh?=
SW620 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;KTWM2OD1zND65NFE1KM7:TR?= Mk\LV2FPT0WU
NCI-H226 M12wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjkRZlLUUN3ME2xOE46ODh3IN88US=> NIO1TGlUSU6JRWK=
SW962 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF2Lkm0N|Ih|ryP MUfTRW5ITVJ?
KYSE-150 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xXnhxUUN3ME2xOE46PTVizszN NF;rVVlUSU6JRWK=
OCUB-M MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O2UGlEPTB;MUSuPVg5OyEQvF2= MmDvV2FPT0WU
ES7 NEnwV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K2UGlEPTB;MUWuNFk5PCEQvF2= NH7t[lRUSU6JRWK=
SW1463 M{nJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3yU|RiUUN3ME2xOU41OjJ|IN88US=> MWfTRW5ITVJ?
CAKI-1 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M121dGlEPTB;MUWuOVM1PiEQvF2= NGfCU4VUSU6JRWK=
MKN28 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELjNVNKSzVyPUG1MlU1PzlizszN M2\0fXNCVkeHUh?=
SW13 NYi2clJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q4dGlEPTB;MUWuOlE5KM7:TR?= NEDxUIpUSU6JRWK=
A3-KAW NYjjfGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD1zNT65Olk4KM7:TR?= MnrZV2FPT0WU
LU-65 M3jKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD1zNT65O|Y5KM7:TR?= NWTpXmNoW0GQR1XS
Calu-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XRZWlEPTB;MU[uNFM3QCEQvF2= NYOzOHJYW0GQR1XS
ST486 M3y1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfDUppKSzVyPUG2MlA1OzFizszN NV7qZYRiW0GQR1XS
BB30-HNC NHnVXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XIXGlEPTB;MU[uNVI1PiEQvF2= M1HOV3NCVkeHUh?=
EGI-1 NYjEfI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHJcIZKSzVyPUG2MlQ1PiEQvF2= MWrTRW5ITVJ?
SH-4 NFvkT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzvWldKSzVyPUG2MlQ4OzFizszN NY\tNWV6W0GQR1XS
MN-60 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[3WJdKSzVyPUG3MlIzQTdizszN MXPTRW5ITVJ?
MPP-89 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLjbpFKSzVyPUG3MlI1PTlizszN MWnTRW5ITVJ?
A2780 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5LkSxN|kh|ryP NXnYRoFOW0GQR1XS
Daoy MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0ZplNUUN3ME2xO{41Pjl3IN88US=> NV24NWxSW0GQR1XS
NCI-H2126 NUnqWY56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QTWM2OD1zNz60O|cyKM7:TR?= NEXm[5JUSU6JRWK=
NCI-H1563 NXHW[Hp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLOTWM2OD1zNz60PVE4KM7:TR?= NWHMcHNOW0GQR1XS
8-MG-BA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnkOpVUUUN3ME2xO{43PjR6IN88US=> MYTTRW5ITVJ?
786-0 NHHad3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF5LkizOVMh|ryP MlvJV2FPT0WU
AM-38 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrOTWM2OD1zNz65N|A3KM7:TR?= MV7TRW5ITVJ?
COLO-824 NYjrUlc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSzTWM2OD1zOD60OFM3KM7:TR?= NH22WWdUSU6JRWK=
SK-MEL-30 M4XQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXufHllUUN3ME2xPE42ODh{IN88US=> NIHsTmZUSU6JRWK=
CESS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTSTWM2OD1zOD63OlA6KM7:TR?= MUDTRW5ITVJ?
BL-70 M4jQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF6LkixOVYh|ryP MkLtV2FPT0WU
NCI-H2170 NF\rUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rTPGlEPTB;MUiuPVE4QSEQvF2= NVHaPXJNW0GQR1XS
HT-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnpWlc2UUN3ME2xPE46QDNizszN MXXTRW5ITVJ?
BOKU MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF7LkCzPFEh|ryP MXnTRW5ITVJ?
HPAF-II M1WzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW2bIVKSzVyPUG5MlMxOTVizszN M1\xWHNCVkeHUh?=
KGN NH;kU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHUVGFKSzVyPUG5MlQ4PjVizszN NYfJVGxGW0GQR1XS
MC-CAR NWPRfmNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31b5NoUUN3ME2xPU43OzF|IN88US=> MoXDV2FPT0WU
BHT-101 M{HDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzITWM2OD1zOT63O|ch|ryP M4r5[XNCVkeHUh?=
SW1783 NU[xcolqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF7Lke4NFYh|ryP M2T2c3NCVkeHUh?=
KP-N-YN NH74fphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW3TWM2OD1{MD6wNlYzKM7:TR?= MVvTRW5ITVJ?
LU-165 NHL0UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NViydWZuUUN3ME2yNE42PTdzIN88US=> MUjTRW5ITVJ?
GOTO MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTqSppKSzVyPUKwMlY1PTFizszN Mk\6V2FPT0WU
EFM-19 M3f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnPTo17UUN3ME2yNU4xPzF4IN88US=> NEK5OHFUSU6JRWK=
CTV-1 NXjvOItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrMeolKSzVyPUKxMlExPTRizszN Mmj4V2FPT0WU
HEL MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDoTWM2OD1{MT60NlE3KM7:TR?= Ml7IV2FPT0WU
SNU-C2B M3PvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jBXGlEPTB;MkGuOFI3KM7:TR?= M4TDS3NCVkeHUh?=
ECC4 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;PbYExUUN3ME2yNU44ODdizszN Mn;PV2FPT0WU
NEC8 NHvFN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njcGlEPTB;MkGuPFM3QCEQvF2= NHjRbVNUSU6JRWK=
KMOE-2 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLtUpI2UUN3ME2yNU45QTJzIN88US=> MkfDV2FPT0WU
NCI-H524 M2D5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjZW49KSzVyPUKyMlA5ODhizszN M3;0T3NCVkeHUh?=
WSU-NHL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrpd45HUUN3ME2yNk4yPTd5IN88US=> NYn2cZhEW0GQR1XS
SF126 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2blFKSzVyPUKyMlI1PjlizszN NVqwU5dsW0GQR1XS
HOP-92 M3jKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHqVWtsUUN3ME2yNk4{OTZ5IN88US=> NGrPPIZUSU6JRWK=
CTB-1 MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojRTWM2OD1{Mj60Olc4KM7:TR?= MUXTRW5ITVJ?
KYSE-270 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SzWmlEPTB;MkKuPVM2PyEQvF2= MXvTRW5ITVJ?
SK-MEL-24 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHaepY{UUN3ME2yN{4yQDdizszN NVvJWY5sW0GQR1XS
Calu-3 M{DH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX2TWM2OD1{Mz6yNVI5KM7:TR?= Mn7jV2FPT0WU
GAMG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ|LkKzOlch|ryP NHrhfIRUSU6JRWK=
SW1573 M3jCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjzclhuUUN3ME2yN{44PDF3IN88US=> MXfTRW5ITVJ?
MHH-NB-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ2LkCxPVQh|ryP MlLaV2FPT0WU
TK10 M{LxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K0Z2lEPTB;MkSuOVAyOyEQvF2= M{LsbXNCVkeHUh?=
LB373-MEL-D M4mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHobJV3UUN3ME2yOE43ODZ2IN88US=> M2S1W3NCVkeHUh?=
KALS-1 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTZTWM2OD1{ND63N|I4KM7:TR?= NFnFToFUSU6JRWK=
HUTU-80 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ3LkiwN|Ih|ryP MWjTRW5ITVJ?
HuP-T3 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rnbWlEPTB;Mk[uNVY4PCEQvF2= MkWxV2FPT0WU
OE19 NXjueXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETzUHdKSzVyPUK2MlIyPTNizszN MWPTRW5ITVJ?
J82 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSyTWM2OD1{Nj6yOFcyKM7:TR?= NWPvcVk4W0GQR1XS
DU-4475 NH;1[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ4LkO4NVkh|ryP M{jme3NCVkeHUh?=
DMS-53 NY\MNGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vCWmlEPTB;Mk[uOVE{QCEQvF2= MY\TRW5ITVJ?
COLO-741 NGDqRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZTWM2OD1{Nj64N|Q1KM7:TR?= NWL2PJo2W0GQR1XS
SW48 M4ntWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1{Nj64PFIh|ryP MorXV2FPT0WU
IGR-1 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ4LkmzN|Qh|ryP NUPWTIFvW0GQR1XS
639-V MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPuTWM2OD1{Nz6wNlQ2KM7:TR?= M1jXTHNCVkeHUh?=
LK-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzOIVKSzVyPUK3MlQyPDFizszN MW\TRW5ITVJ?
NCI-H2347 NF7CNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P1bmlEPTB;MkeuPVY6QSEQvF2= NELzbmRUSU6JRWK=
NCI-H2228 M333Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTnXoVKSzVyPUK4MlA6ODVizszN MkXRV2FPT0WU
LS-123 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4SWU{UUN3ME2yPE4yOjZ{IN88US=> M3e0eHNCVkeHUh?=
U031 NYHZW4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJ6LkK1NkDPxE1? MVHTRW5ITVJ?
NCI-H1792 NIjzTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHrOGw{UUN3ME2yPE41PzJzIN88US=> NVLle4ozW0GQR1XS
NCI-H2087 M4DxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO0epdKSzVyPUK4Mlc2PTJizszN MmO5V2FPT0WU
NCI-H2342 NHjWRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDNNo9wUUN3ME2yPU42OjB6IN88US=> MlLTV2FPT0WU
SW626 NYTHd3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe0UVNKSzVyPUK5Mlc2PiEQvF2= NF;DU3JUSU6JRWK=
LB2518-MEL NVnBdZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\FcnJuUUN3ME2yPU45OTVizszN M1T0eHNCVkeHUh?=
RXF393 NYrtd2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\seGFKSzVyPUOwMlA6PTJizszN MluxV2FPT0WU
LC4-1 M{LFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzo[WdKSzVyPUOwMlMxQTJizszN NW\GdXdMW0GQR1XS
NCI-H1694 M1TiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqxfZJKSzVyPUOwMlY3OjRizszN NGqzXotUSU6JRWK=
K5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHI[G9YUUN3ME2zNE46PzB{IN88US=> M3HFeXNCVkeHUh?=
HDLM-2 NFj1cVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD1|MD65O|I2KM7:TR?= M1;wNHNCVkeHUh?=
BCPAP NYrVV|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TLWWlEPTB;M{GuPFM4QSEQvF2= MVHTRW5ITVJ?
BC-3 M2fDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLzTWM2OD1|Mj6xOFA{KM7:TR?= NH30[3NUSU6JRWK=
LB996-RCC NV3Yb5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVN4FkUUN3ME2zNk4zOzV6IN88US=> MUjTRW5ITVJ?
NCI-H2009 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvXRXdZUUN3ME2zNk41QThzIN88US=> NUKzUHQzW0GQR1XS
HTC-C3 NVTu[|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCNXNHUUN3ME2zN{44PTF7IN88US=> NYTtclZnW0GQR1XS
LAMA-84 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfQTWM2OD1|ND60OFA4KM7:TR?= MX7TRW5ITVJ?
CCRF-CEM NXvON2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN2LkW3NVUh|ryP MYDTRW5ITVJ?
AN3-CA NU\UfJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D2OWlEPTB;M{WuNFU3QCEQvF2= Mo\6V2FPT0WU
NCI-H1734 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;0R2lEPTB;M{WuNlU3OSEQvF2= M2q0XnNCVkeHUh?=
Ca-Ski NYTldJVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLlTWM2OD1|NT60NVAyKM7:TR?= NHHHblZUSU6JRWK=
U-266 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTIW|lQUUN3ME2zOU43OTF2IN88US=> M1vpdHNCVkeHUh?=
SBC-5 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LlbGlEPTB;M{WuO|c5OSEQvF2= MmDIV2FPT0WU
GT3TKB NFX6cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN5LkGxOUDPxE1? NGrJcHVUSU6JRWK=
MDA-MB-175-VII NGfp[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuwTWM2OD1|Nz6yNlQ5KM7:TR?= M1G3UXNCVkeHUh?=
PFSK-1 NIroUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN5LkK0N|Uh|ryP MnrPV2FPT0WU
IMR-5 M4H5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW3ZW9KSzVyPUO3MlI1QDdizszN MU\TRW5ITVJ?
Daudi NYPXO|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofaTWM2OD1|Nz6zOVk4KM7:TR?= MVvTRW5ITVJ?
A498 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;QTWM2OD1|Nz63NlE5KM7:TR?= MoXiV2FPT0WU
SCC-4 NV\jVZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN5Lke4OFMh|ryP MVfTRW5ITVJ?
COLO-680N NIqweZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF25RnJKSzVyPUO4MlI5QDVizszN NFnRRZlUSU6JRWK=
SK-MES-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN6LkOyNVUh|ryP NVrTNpduW0GQR1XS
SR M3zkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzSnBKSzVyPUO4MlU1QTVizszN M2rReXNCVkeHUh?=
LNCaP-Clone-FGC NX3ac5p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPybGpuUUN3ME2zPE42PjN5IN88US=> NGnyUIVUSU6JRWK=
SK-HEP-1 NUXiOG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPwfpdKSzVyPUO4Mlc5OjJizszN MXnTRW5ITVJ?
BPH-1 NIXKPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN6LkizNlkh|ryP MVHTRW5ITVJ?
NCI-H1755 NIXQXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfDTWM2OD1|OT61PFE4KM7:TR?= MVjTRW5ITVJ?
LXF-289 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN7LkiwPFQh|ryP MVjTRW5ITVJ?
SW1088 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPNTWM2OD12MD6yNVA4KM7:TR?= M4LjZXNCVkeHUh?=
MOLT-4 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\z[ZVKSzVyPUSwMlI6ODFizszN MUPTRW5ITVJ?
AsPC-1 NF\lPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRyLkS1PFMh|ryP MX;TRW5ITVJ?
HOP-62 M2DWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7nU3lIUUN3ME20NE43PTZ6IN88US=> NYPlb5VyW0GQR1XS
A172 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpUGlEPTB;NECuPFUyOSEQvF2= M4fLfXNCVkeHUh?=
SN12C NYTPOG1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHv[mhKSzVyPUSwMlk{QDVizszN MknCV2FPT0WU
MDA-MB-231 NXvoVoVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HtVGlEPTB;NECuPVg6QCEQvF2= NGXmXWpUSU6JRWK=
RPMI-2650 NVTxd4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSUlNKSzVyPUSxMlE2QTNizszN NWe1T3l4W0GQR1XS
KYSE-140 M2nzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTnO3JTUUN3ME20NU45OTJ|IN88US=> NX7MfZB{W0GQR1XS
KINGS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;aTWM2OD12Mj60Olk4KM7:TR?= NV73bHdoW0GQR1XS
HSC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT5O2tKSzVyPUSyMlY3PjFizszN NYPqNZFCW0GQR1XS
PC-14 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETpOW1KSzVyPUSzMlE5QDJizszN NX7U[2pTW0GQR1XS
COR-L105 NYfnXo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX5TWM2OD12Mz62OVAzKM7:TR?= NULtWmtRW0GQR1XS
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfqTWM2OD12ND6yN|cyKM7:TR?= MmflV2FPT0WU
NCI-H661 NYPXVpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD12ND6yPVU5KM7:TR?= NVj5UJZwW0GQR1XS
IST-MEL1 NFS5bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfTbnVVUUN3ME20OE4{PTl7IN88US=> Moe3V2FPT0WU
HCC1806 NFzxNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi0cFhKSzVyPUS0MlU5PzNizszN NHrRbphUSU6JRWK=
COLO-800 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH2TWM2OD12ND64OFU{KM7:TR?= NUWxUWNSW0GQR1XS
IST-SL2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR3LkGyOFch|ryP MVfTRW5ITVJ?
8305C NUm0ZoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHITWM2OD12NT6zNFkh|ryP NXvBTVFGW0GQR1XS
UACC-62 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD12Nj6yPFc2KM7:TR?= NF[5VVFUSU6JRWK=
COR-L23 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWWpFKSzVyPUS3MlE6QSEQvF2= NUTN[ZVoW0GQR1XS
EFE-184 NIDlTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzrTWM2OD12Nz6zPFgh|ryP NUn5eXQ5W0GQR1XS
DMS-114 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR5LkSxOFkh|ryP NIHmVmhUSU6JRWK=
KYSE-520 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7VTWM2OD12OD61N|E2KM7:TR?= MlPUV2FPT0WU
SNG-M NFPxNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPMfW9IUUN3ME20PU41OzRizszN M2DIOnNCVkeHUh?=
A2058 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C2NGlEPTB;NEmuOFg5PSEQvF2= MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID